Management of polycystic liver disease

被引:23
|
作者
Everson G.T. [1 ]
Taylor M.R.G. [1 ]
机构
[1] Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO 80262
基金
美国国家卫生研究院;
关键词
Autosomal Dominant Polycystic Kidney Disease; Cystic Disease; Hepatic Cyst; Autosomal Recessive Polycystic Kidney Disease; Polycystic Liver Disease;
D O I
10.1007/s11894-005-0061-6
中图分类号
学科分类号
摘要
The adult forms of polycystic liver disease are characterized by autosomal dominant inheritance and numerous hepatic cysts, with or without renal involvement. Mutations in two distinct genes predispose to renal and liver cysts (PKD1 and PKD2), and mutations in two different genes yield isolated liver cysts (PRKCSH and SEC63). Mutations at certain loci of PKD1 may predispose to more severe renal cystic disease or cerebral aneurysms. Risk factors for severe hepatic cystic disease include aging, female sex, pregnancy, use of exogenous female steroid hormones, degree of renal cystic disease, or severity of renal dysfunction (in patients with mutations in PKD1 or PKD2). Although liver failure or complications of advanced liver disease is rare, some patients develop massive hepatic cystic disease and become clinically symptomatic. There is no effective medical therapy. Treatment options include cyst aspiration and sclerosis, open or laparoscopic cyst fenestration, hepatic resection, and liver transplantation. © Current Science Inc. 2005.
引用
收藏
页码:19 / 25
页数:6
相关论文
共 50 条
  • [21] Tamoxifen for the treatment of polycystic liver disease A case report
    Aapkes, Sophie E.
    Bernts, Lucas H. P.
    van den Berg, M.
    Gansevoort, Ron T.
    Drenth, Joost P. H.
    MEDICINE, 2021, 100 (32) : E26797
  • [22] Orthotopic liver transplantation in polycystic liver disease
    Arredondo, Jorge
    Rotellar, Fernando
    Herrero, Ignacio
    Pedano, Nicolas
    Marti, Pablo
    Zozaya, Gabriel
    Bellver, Manuel
    Pardo, Fernando
    CIRUGIA ESPANOLA, 2013, 91 (10): : 659 - 663
  • [23] Exploring the innate immune response in polycystic liver disease
    Duijzer, Renee
    Dalloyaux, Daisy
    Boerrigter, Melissa M.
    Lemmers, Heidi
    Dijkstra, Helga
    van Emst, Liesbeth
    te Morsche, Rene H. M.
    Jaeger, Martin
    Joosten, Leo A. B.
    Drenth, Joost P. H.
    CYTOKINE, 2024, 184
  • [24] Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease
    Yang, Jaeseok
    Ryu, Hyunjin
    Han, Miyeun
    Kim, Hyunsuk
    Hwang, Young-Hwan
    Chung, Jin Wook
    Yi, Nam-Joon
    Lee, Kwang-Woong
    Suh, Kyung-Suk
    Curie Ahn
    HEPATOLOGY RESEARCH, 2016, 46 (02) : 183 - 191
  • [25] Highly symptomatic adult polycystic liver disease: Options and results of surgical management
    Tan, YM
    Ooi, LL
    ANZ JOURNAL OF SURGERY, 2004, 74 (08) : 653 - 657
  • [26] Isolated polycystic liver disease not linked to polycystic kidney disease 1 and 2
    Iglesias, DM
    Palmitano, JA
    Arrizurieta, E
    Kornblihtt, AR
    Herrera, M
    Bernath, V
    Martin, RS
    DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (02) : 385 - 388
  • [27] Isolated Polycystic Liver Disease Not Linked to Polycystic Kidney Disease 1 and 2
    Diana M. Iglesias
    Juan A. Palmitano
    Elvira Arrizurieta
    Alberto R. Kornblihtt
    Mariana Herrera
    Viviana Bernath
    Rodolfo S. Martin
    Digestive Diseases and Sciences, 1999, 44 : 385 - 388
  • [28] Laparoscopic palliation of polycystic liver disease
    Robinson, TN
    Stiegmann, GV
    Everson, GT
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2005, 19 (01): : 130 - 132
  • [29] Therapeutic Targets in Polycystic Liver Disease
    Masyuk, Tatyana V.
    Masyuk, Anatoliy I.
    LaRusso, Nicholas F.
    CURRENT DRUG TARGETS, 2017, 18 (08) : 950 - 957
  • [30] Overexpression of Aquaporin 1 on cysts of patients with polycystic liver disease
    Li, Dingyang
    Shi, Xiaoju
    Zhao, Lijing
    Liang, Zuowen
    Xie, Shuli
    Wang, Guangyi
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2016, 108 (02) : 71 - 78